EP2281877A3
(de)
*
|
2003-05-21 |
2011-06-01 |
Genzyme Corporation |
Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
|
CN101528916B
(zh)
|
2006-04-28 |
2013-09-04 |
宾夕法尼亚大学托管会 |
规模可调的aav生产方法
|
PL3581650T3
(pl)
*
|
2008-09-15 |
2023-05-22 |
Uniqure Biopharma B.V. |
Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania
|
BR112012018899A2
(pt)
|
2010-01-28 |
2015-09-15 |
Philadelphia Children Hospital |
"método para purificar partículas de vetor de vírus adeno-associado."
|
MX2015014568A
(es)
|
2013-04-17 |
2016-12-02 |
Genzyme Corp |
Composiciones y metodos para tratar y prevenir la degeneracion macular.
|
ES2690643T3
(es)
|
2013-11-26 |
2018-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Vectores virales adeno-asociados para el tratamiento de enfermedad de almacenamiento de glucógeno
|
GB201401707D0
(en)
*
|
2014-01-31 |
2014-03-19 |
Sec Dep For Health The |
Adeno-associated viral vectors
|
RU2703145C2
(ru)
|
2014-02-06 |
2019-10-15 |
Джензим Корпорейшн |
Композиции и способы лечения и предотвращения дегенерации желтого пятна
|
WO2015160977A1
(en)
*
|
2014-04-15 |
2015-10-22 |
Kiromic, Llc |
Compositions and methods for treating cardiovascular diseases using smad3
|
WO2015168666A2
(en)
|
2014-05-02 |
2015-11-05 |
Genzyme Corporation |
Aav vectors for retinal and cns gene therapy
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
US10526583B2
(en)
|
2014-07-02 |
2020-01-07 |
University Of Florida Research Foundation, Incorporated |
Compositions and methods for purifying recombinant adeno-associated virus
|
CN112553229A
(zh)
|
2014-11-05 |
2021-03-26 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
KR102599909B1
(ko)
|
2014-11-14 |
2023-11-09 |
보이저 테라퓨틱스, 인크. |
근위축성 측삭 경화증(als)을 치료하는 조성물 및 방법
|
DK3218386T3
(da)
|
2014-11-14 |
2021-06-07 |
Voyager Therapeutics Inc |
Modulatorisk polynukleotid
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
CN107636153B
(zh)
|
2014-12-23 |
2020-12-11 |
美国政府(由卫生和人类服务部的部长所代表) |
编码经修饰的g6pc的腺相关病毒载体及其用途
|
CA2974378A1
(en)
|
2015-01-20 |
2016-07-28 |
Genzyme Corporation |
Analytical ultracentrifugation for characterization of recombinant viral particles
|
PT3256594T
(pt)
|
2015-02-10 |
2022-01-18 |
Genzyme Corp |
Entrega intensificada de partículas virais ao corpo estriado e córtex
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
CN108093639B
(zh)
|
2015-04-16 |
2022-07-19 |
埃默里大学 |
用于肝脏中蛋白质表达的重组启动子和载体及其用途
|
EP3285813B1
(de)
|
2015-04-23 |
2020-12-23 |
Washington State University |
Smad7-genverabreichung als therapeutikum
|
RU2021132397A
(ru)
|
2015-05-16 |
2022-02-24 |
Джензим Корпорейшн |
Генное редактирование глубоких интронных мутаций
|
US10954492B2
(en)
|
2015-06-10 |
2021-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Processes for production and purification of nucleic acid-containing compositions
|
CN108431216B
(zh)
|
2015-10-21 |
2022-08-05 |
美国政府(由卫生和人类服务部的部长所代表) |
经密码子优化的尺寸减小的atp7a cdna及用于治疗铜转运障碍的用途
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
WO2017100676A1
(en)
*
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
ES2918998T3
(es)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Método de purificación escalable para AAVrh10
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
EP3387138B1
(de)
|
2015-12-11 |
2022-01-26 |
The Trustees Of The University Of Pennsylvania |
Skalierbares reinigungsverfahren für aav9
|
KR20180098294A
(ko)
|
2015-12-15 |
2018-09-03 |
젠자임 코포레이션 |
뮤코지질증 ii형을 치료하기 위한 아데노-관련 바이러스 벡터
|
FI3411484T3
(fi)
|
2016-02-05 |
2023-11-15 |
Univ Emory |
Yksisäikeisen tai itsekomplementaarisen adenoassosioidun viruksen 9 injektio serebrospinaaliseen fluidiin
|
JP6645279B2
(ja)
*
|
2016-03-11 |
2020-02-14 |
セイコーエプソン株式会社 |
撮影装置
|
HUE056854T2
(hu)
*
|
2016-03-31 |
2022-03-28 |
Spark Therapeutics Inc |
Oszlop alapú, teljes mértékben méretezhetõ rAAV elõállítási eljárás
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
AU2017267665C1
(en)
|
2016-05-18 |
2023-10-05 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
CA3024449A1
(en)
|
2016-05-18 |
2017-11-23 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
GB201612248D0
(en)
*
|
2016-07-14 |
2016-08-31 |
Puridify Ltd |
New process
|
MX2019001938A
(es)
|
2016-08-15 |
2019-07-04 |
Genzyme Corp |
Metodos para detectar aav.
|
EP3510161A4
(de)
|
2016-08-23 |
2020-04-22 |
Akouos, Inc. |
Zusammensetzungen und verfahren zur behandlung von nicht altersbedingten hörschäden bei einer person
|
AU2017321488B2
(en)
|
2016-08-30 |
2022-10-20 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
US11000561B2
(en)
*
|
2016-11-04 |
2021-05-11 |
Takeda Pharmaceutical Company Limited |
Adeno-associated virus purification methods
|
US10294452B2
(en)
*
|
2016-11-22 |
2019-05-21 |
Dao-Yao He |
Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
|
MX2019012113A
(es)
|
2017-04-14 |
2020-09-10 |
Univ Nat Taiwan |
Terapia génica para la deficiencia de la aadc.
|
AU2018261003A1
(en)
|
2017-05-05 |
2019-11-14 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's Disease
|
US11603542B2
(en)
|
2017-05-05 |
2023-03-14 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
JP2020519272A
(ja)
|
2017-05-09 |
2020-07-02 |
エモリー ユニバーシティー |
凝固因子変異体及びその使用
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
PE20200737A1
(es)
*
|
2017-06-30 |
2020-07-23 |
Spark Therapeutics Inc |
Metodos de purificacion de columna de vector aav
|
AU2018302016A1
(en)
|
2017-07-17 |
2020-02-06 |
The Regents Of The University Of California |
Trajectory array guide system
|
CA3071978A1
(en)
|
2017-08-03 |
2019-02-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
TWI804518B
(zh)
|
2017-10-16 |
2023-06-11 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
JP7356994B2
(ja)
|
2018-03-02 |
2023-10-05 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
網膜炎症および神経変性を処置するためのil-34の使用
|
EP3762500A1
(de)
|
2018-03-06 |
2021-01-13 |
Voyager Therapeutics, Inc. |
Aus insektenzelle hergestellte teilweise selbstkomplementäre aav-genome
|
WO2019210137A1
(en)
|
2018-04-27 |
2019-10-31 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of aadc viral vectors
|
US20210230632A1
(en)
|
2018-05-15 |
2021-07-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
CA3099306A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
WO2019222441A1
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
EP3793615A2
(de)
|
2018-05-16 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Gerichtete entwicklung von aav zur verbesserung des tropismus für zns
|
CN112567035A
(zh)
|
2018-07-02 |
2021-03-26 |
沃雅戈治疗公司 |
肌萎缩侧索硬化症及脊髓相关病症的治疗
|
MX2021000810A
(es)
|
2018-07-24 |
2021-04-28 |
Voyager Therapeutics Inc |
Sistemas y metodos para producir formulaciones de terapia genetica.
|
CA3115217A1
(en)
|
2018-10-02 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
JP2022504740A
(ja)
|
2018-10-12 |
2022-01-13 |
ジェンザイム・コーポレーション |
肝臓に向けられた遺伝子補充療法によって重度のpkuを処置するための改善されたヒトpahの生成
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
EP4257155A3
(de)
|
2018-11-16 |
2024-02-28 |
Encoded Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von morbus wilson
|
US20220017922A1
(en)
|
2018-12-18 |
2022-01-20 |
Ultragenyx Pharmaceutical Inc. |
Methods and compositions for treating glycogen storage diseases
|
SG11202106855YA
(en)
|
2019-01-04 |
2021-07-29 |
Ultragenyx Pharmaceutical Inc |
Gene therapy constructs for treating wilson disease
|
JP2022522995A
(ja)
|
2019-01-18 |
2022-04-21 |
ボイジャー セラピューティクス インコーポレイテッド |
Aav粒子を生成するための方法及びシステム
|
WO2020214676A1
(en)
*
|
2019-04-15 |
2020-10-22 |
Children's Hospital Medical Center |
Viral vector manufacturing methods
|
JP2022530126A
(ja)
|
2019-04-23 |
2022-06-27 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
新規アデノ随伴ウイルス(aav)バリアント及び遺伝子治療のためのその使用
|
TW202106879A
(zh)
|
2019-04-29 |
2021-02-16 |
美商航海家醫療公司 |
於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
US20220290182A1
(en)
|
2019-08-09 |
2022-09-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
EP4022070A1
(de)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Kontrollierte expression viraler proteine
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
WO2021062012A1
(en)
|
2019-09-25 |
2021-04-01 |
Emory University |
Use of klk10 and engineered derivatizations thereof
|
WO2021124152A1
(en)
|
2019-12-19 |
2021-06-24 |
Pfizer Inc. |
Compositions and methods for nucleic acid transfection using cationic polymers and stabilizers
|
US20230066585A1
(en)
|
2020-01-17 |
2023-03-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Gene therapy for treatment of crx-autosomal dominant retinopathies
|
CA3165019A1
(en)
|
2020-01-29 |
2021-08-05 |
Amy FREDERICK |
Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
|
AU2021218703A1
(en)
|
2020-02-14 |
2022-07-28 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating CDKL5 deficiency disorder
|
EP3868886A1
(de)
*
|
2020-02-21 |
2021-08-25 |
Bia Separations D.O.O. |
Verfahren zur trennung oder abreicherung von leeren aav-kapsiden aus vollen aav-kapsiden
|
EP4114958A1
(de)
|
2020-02-21 |
2023-01-11 |
Akouos, Inc. |
Zusammensetzungen und verfahren zur behandlung von nicht altersbedingten hörschäden bei einer person
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
AU2021257848A1
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
GB202005732D0
(en)
|
2020-04-20 |
2020-06-03 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
TW202208397A
(zh)
|
2020-05-13 |
2022-03-01 |
美商航海家醫療公司 |
Aav蛋白殼之趨性重定向
|
US20220033782A1
(en)
*
|
2020-07-29 |
2022-02-03 |
Pall Corporation |
Adenovirus-associated viruses separation method
|
EP4192514A1
(de)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
|
EP3957378B1
(de)
*
|
2020-08-18 |
2023-05-17 |
Sartorius BIA Separations d.o.o. |
Multimodale metallaffinitätsverarbeitung von aav-kapsiden
|
CN116261483A
(zh)
*
|
2020-08-18 |
2023-06-13 |
赛多利斯比亚分离有限责任公司 |
多模式金属亲和加工衣壳
|
JPWO2022045055A1
(de)
*
|
2020-08-24 |
2022-03-03 |
|
|
GB202013940D0
(en)
|
2020-09-04 |
2020-10-21 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
WO2022061002A1
(en)
|
2020-09-18 |
2022-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
CA3193866A1
(en)
|
2020-10-01 |
2022-04-07 |
Sirkka R.M. Kyostio-Moore |
Human pah expression cassette for treatment of pku by liver-directed gene replacement therapy
|
CA3197726A1
(en)
|
2020-10-15 |
2022-04-21 |
Simon Auslaender |
Nucleic acid constructs for simultaneous gene activation
|
IL302046A
(en)
|
2020-10-15 |
2023-06-01 |
Hoffmann La Roche |
Nucleic acid structures for va RNA transcription
|
IL302128A
(en)
|
2020-11-02 |
2023-06-01 |
Biomarin Pharm Inc |
A process for the enrichment of adeno-associated virus
|
US20230399656A1
(en)
|
2020-11-03 |
2023-12-14 |
Pfizer Inc. |
Methods for Purification of AAV Vectors by Anion Exchange Chromatography
|
US11821000B2
(en)
|
2020-11-10 |
2023-11-21 |
Dionex Corporation |
Method of separating viral vectors
|
TW202246516A
(zh)
|
2021-03-03 |
2022-12-01 |
美商航海家醫療公司 |
病毒蛋白之控制表現
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
CN117460832A
(zh)
|
2021-03-22 |
2024-01-26 |
建新公司 |
空aav衣壳和完整aav衣壳的尺寸排阻色谱分析
|
KR20240021231A
(ko)
*
|
2021-06-11 |
2024-02-16 |
스파크 테라퓨틱스, 인코포레이티드 |
Aav 벡터 컬럼 정제 방법
|
GB202110014D0
(en)
*
|
2021-07-12 |
2021-08-25 |
Cytiva Bioprocess R & D Ab |
A method for separating adeno-associated virus capsids, compositions obtained by said method and uses thereof
|
WO2023012514A1
(en)
*
|
2021-08-04 |
2023-02-09 |
Takeda Pharmaceutical Company, Limited |
Adeno-associated virus separation on a cation exchanger
|
WO2023034994A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034996A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034990A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034980A1
(en)
|
2021-09-03 |
2023-03-09 |
Bomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034997A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034989A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
CA3235632A1
(en)
|
2021-11-02 |
2023-05-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023091948A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023111580A1
(en)
|
2021-12-16 |
2023-06-22 |
University Of Dundee |
Targeted degradation of alpha-synuclein
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
WO2023154693A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
GB202201713D0
(en)
|
2022-02-10 |
2022-03-30 |
Univ Dundee |
An affinity directed phosphatase system for targeted protein dephosphorylation
|
WO2023174974A1
(en)
|
2022-03-18 |
2023-09-21 |
Merck Patent Gmbh |
Methods and compositions for purifying adeno associated virus particles
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
WO2023201274A1
(en)
|
2022-04-12 |
2023-10-19 |
Genzyme Corporation |
Use of an irak4 modulator for gene therapy
|
WO2023201272A1
(en)
|
2022-04-12 |
2023-10-19 |
Genzyme Corporation |
Use of irak4 modulators for gene therapy
|
TW202405430A
(zh)
|
2022-04-12 |
2024-02-01 |
美商健臻公司 |
對於基因療法藥劑的先天免疫原性之樹突細胞試驗
|
WO2023198685A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Method for determining aav genomes
|
TW202403049A
(zh)
|
2022-05-16 |
2024-01-16 |
美商健臻公司 |
治療異染性白質失養症之方法
|
WO2023227438A1
(en)
|
2022-05-23 |
2023-11-30 |
F. Hoffmann-La Roche Ag |
Raman-based method for the differentiation of aav particle serotype and aav particle loading status
|
WO2023235791A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023232922A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2023240062A1
(en)
|
2022-06-07 |
2023-12-14 |
Adverum Biotechnologies, Inc. |
Melanopsin variants for vision restoration
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024013239A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2024056561A1
(en)
|
2022-09-12 |
2024-03-21 |
F. Hoffmann-La Roche Ag |
Method for separating full and empty aav particles
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
WO2024064856A1
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of cardiomyopathy with aav gene therapy vectors
|